SEC Form 4 · accession 0001012975-18-000467
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Enright
Officer — President and CEO · Director
Period of report
May 25, 2018
Accepted (ET)
May 29, 2018 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001F1 | May 25, 2018 | P | 1,300 | $0.5076 | A | 365,839 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was executed in multiple trades at prices ranging from $0.505151 to $0.5088. The price above reflects the weighted average purchase price. Detailed information regarding the number of shares purchased at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.